无锡药明康德新药开发股份有限公司 2025 年第二次临时股东大会 会议材料 二〇二五年九月 无锡药明康德新药开发股份有限公司 股东大会会议须知 为了维护全体股东的合法权益、保障股东依法行使股东权利，确保股东大会 的正常秩序和议事效率，根据中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司股东会规则》及《无锡药明康德新药开发股份有限公司章程》《无锡 药明康德新药开发股份有限公司股东大会议事规则》，特制订本须知。 一、公司设董事会办公室，具体负责大会有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益，确保大会正常秩序， 提高议事效率为原则，认真行使法定权利并履行法定职责。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股东（或 其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的律师和董事会 邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、为及时、准确统计出席股东大会的股东人数及所持有表决权的股份数量， 出席会议的股东（或其授权代表）请按照股东大会通知中载明的会议登记办法在 会议召开前向董事会办公室办理签到登记手续。 五、股东（或其授权代表）依法享有发言权、咨 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-058 无锡药明康德新药开发股份有限公司 第三届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 8 月 28 日向本公司全体董事发出会议通知及会议材料，以通讯表决方式 于 2025 年 9 月 2 日召开第三届董事会第二十五次会议。本次董事会会议应出席 董事 11 人，实际出席董事 11 人，会议由董事长 Ge Li（李革）召集。本次董事 会符合《中华人民共和国公司法》和《无锡药明康德新药开发股份有限公司章程》 （以下简称"《公司章程》"）关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于取消监事会、变更公司注册资本、修改公司章程并办 理工商变更登记的议案》 同意公司取消监事会，于经修订后的《公司章程》生效之日，《无锡药明康 德新药开发股份有限公司监事会议事规则》同步予以废止；同意公司注册资本由 2,88 ...

Core Viewpoint - The global drug development model has fundamentally shifted from a "solo" approach to a collaborative one, with the rise of the CXO industry accelerating new drug development processes [1] Group 1: CRDMO Model - WuXi AppTec's CRDMO model integrates the entire drug development process from research (R) to development (D) and commercialization (M), allowing the company to capture industry innovation trends and provide downstream business support [2] - The CRDMO model has enabled WuXi AppTec to establish partnerships with over 150 companies in the targeted protein degradation (TPD) field, synthesizing more than 188,000 complex TPD compounds, with over 70 entering preclinical stages and more than 10 in late-stage development [2] Group 2: Operational Efficiency - The integrated CRDMO model facilitates seamless collaboration among multiple teams, reducing costs and project transfer risks, thus enhancing the efficiency of new drug development [3] - WuXi AppTec has expanded its global footprint from a single 650-square-meter lab to nearly 30 R&D and production bases worldwide, optimizing facility utilization and lowering investment costs and risks [4] Group 3: Financial Performance - WuXi TIDES reported a revenue of 5.03 billion yuan in the first half of 2025, reflecting a year-on-year growth of 141.6%, making it one of the fastest-growing segments for WuXi AppTec [5] - The company is also expanding its small molecule production capacity, with projections indicating that the total reactor volume at its Changzhou and Taixing facilities will exceed 4 million liters by the end of 2025 [5] Group 4: Quality and Compliance - WuXi AppTec's global operations adhere to high-quality standards, as evidenced by its two API production bases in Changzhou and Taixing passing FDA inspections without any non-compliance issues [6] Group 5: Workforce and Culture - The company has grown its team from 100 process chemists to over 3,000, enhancing its ability to meet diverse client needs without delays [7] - WuXi AppTec emphasizes its commitment to supporting drug discovery, development, and production, aiming to benefit the industry, clients, and ultimately patients [7]

药明康德成交额达100亿元，现涨2.26%。 ...

Core Viewpoint - The market is experiencing a shift towards large-cap growth stocks, with institutional funds favoring companies with strong fundamentals and high cash flow certainty. Group 1: Market Performance - As of September 1, 2025, the large-cap growth index rose by 15.03% in August, outperforming the Shanghai Composite Index, CSI 300, and CSI 2000, which increased by 7.97%, 10.33%, and 9.67% respectively [1] - The large-cap growth ETF (159203) saw a 4.56% increase over the past week, with a current price of 1.23 yuan and a trading volume of 163.07 million yuan [1] Group 2: Institutional Insights - There is a preference for large-cap companies with solid fundamentals and high cash flow, indicating a shift from small-cap stocks to technology and large-cap growth sectors [3][4] - The dividend sector is showing differentiation, with a broader focus on quality cash flow and low volatility rather than solely on dividend yield [3] Group 3: ETF Details - The large-cap growth ETF tracks the National Growth Index and includes major companies like Kweichow Moutai (12%), CATL (10%), and Zijin Mining (4%) among its top holdings [5][9] - The ETF's latest size reached 158.12 million yuan, marking a one-month high, with a maximum monthly return of 14.97% since inception [6] - The ETF has a management fee of 0.50% and a custody fee of 0.10% [7]

Core Insights - On September 1, 28 out of 31 primary industries in the Shenwan index received net financing inflows, with the electronics sector leading at a net inflow of 5.58 billion [1] - Other notable sectors with significant net inflows include telecommunications, non-ferrous metals, power equipment, automotive, and non-bank financials, each exceeding 2 billion in net inflows [1] Industry Summary - The electronics industry topped the list with a net financing inflow of 5.58 billion [1] - Telecommunications, non-ferrous metals, power equipment, automotive, and non-bank financials also showed strong performance with net inflows exceeding 2 billion each [1] Company Summary - A total of 2062 stocks experienced net financing inflows on September 1, with 89 stocks having inflows over 100 million [1] - BYD led individual stocks with a net inflow of 1.401 billion, followed by companies like Xinyi Semiconductor, Zhongji Xuchuang, Zijin Mining, Hanwha, Zhaoyi Innovation, Tongfu Microelectronics, WuXi AppTec, and China Ping An, all exceeding 500 million in net inflows [1]

Group 1 - Major financial institutions like JPMorgan, Citigroup, and Morgan Stanley have recently increased their holdings in H-shares such as CATL, ZTE, and WuXi AppTec, indicating a growing interest in these stocks [1] - JPMorgan's long position in CATL H-shares rose from 5.98% to 6.06%, while Morgan Stanley's increased from 4.96% to 6.05% [1] - The Hong Kong stock market showed strong performance in August, with the Hang Seng Index rising by 1.23% and the Hang Seng Tech Index increasing by 4.06% [3] Group 2 - There is a concern that retail investors often enter the market after institutions have already made their moves, leading to potential losses for these investors [5] - A notable example of institutional behavior is highlighted, where foreign institutions claimed to avoid thematic stocks but were found heavily invested in restructuring concept stocks after earnings reports were released [6] - The concept of "institutional inventory" is introduced as a key indicator of institutional trading activity, suggesting that active participation by institutions can signal future stock performance [9][11] Group 3 - The article emphasizes the importance of understanding the true flow of funds rather than relying on news, which often lags behind actual market movements [14] - It is suggested that retail investors should focus on analyzing data that reveals institutional actions to avoid being misled by superficial news [14] - The conclusion stresses that those who can access and interpret real data will have a competitive advantage in the market [14]

Core Viewpoint - The introduction of the new "National Nine Articles" has led to an increase in the frequency and stability of interim dividends among listed companies in the Shanghai market, with a record number of companies announcing dividend plans in 2025 [1][3]. Group 1: Dividend Trends - As of August 30, 2025, 406 companies in the Shanghai market have announced interim dividend plans, setting new records for both the number of companies and the total dividend amount [1]. - Nearly 60% of these companies have consistently paid interim dividends for two consecutive years, with 233 companies accounting for 58% of the total, distributing a combined dividend of 488.4 billion yuan, which is nearly 90% of this year's interim dividends [2][3]. - The average cash dividend payout ratio for the 2025 interim reports is approximately 57.42%, a significant increase from 40.95% in 2024 [6]. Group 2: High Dividend Companies - Among the 233 companies, 55 have announced dividends exceeding 500 million yuan, with 76% maintaining or increasing their dividend amounts compared to the previous period [4]. - Notable companies with substantial interim dividends include China Mobile, which plans to distribute over 54 billion yuan, and China Telecom, which announced a dividend of 16.581 billion yuan, reflecting an 8% year-on-year increase [3][8]. Group 3: New Entrants to Dividend Payments - Of the 406 companies, 173 are making interim dividend payments for the first time since the introduction of the new policy, indicating a broadening of the dividend distribution landscape [5]. - Companies like Haier Smart Home and WuXi AppTec have initiated interim dividends, with Haier distributing over 2.5 billion yuan, representing 20.83% of its net profit [5]. Group 4: Exceptional Dividend Ratios - Fourteen companies have reported dividend payout ratios exceeding 100%, with over half of the listed companies having payout ratios between 30% and 100% [7]. - For instance, Henan Siwei Automation Equipment Co., Ltd. plans to distribute 8.01 billion yuan, which is 263.77% of its net profit for the period [7].

Market Overview - The A-share market experienced a positive start in September, with the Shanghai Composite Index closing at 3875.53 points, up 0.46%, and the Shenzhen Component Index at 12828.95 points, up 1.05% [1] Fund Flow Analysis - On September 1, the overall net outflow of main funds was -571.43 billion, indicating a cautious approach from institutional investors, with large orders showing significant outflows [1][4] - In contrast, retail investors showed optimism, with net inflows of 537.54 billion from small orders and 33.89 billion from medium orders [1][4] Sector Performance - The main sectors attracting net inflows included medical services, biological products, and chemical pharmaceuticals, with notable inflows of 15.29 billion in medical services, 11.80 billion in biological products, and 11.27 billion in chemical pharmaceuticals [2] - Technology sectors, particularly software development and semiconductors, also saw significant small order inflows of 44.35 billion and 37.19 billion, respectively [2] Market Sentiment - A public fund manager noted that the overall market valuation is high, with the static price-to-earnings ratio reaching 90% of the past decade's levels, indicating potential structural bubbles, particularly in hot technology sectors [3] - Despite the cautious stance of institutional investors, the market remains healthy, with retail investors beginning to enter, suggesting increased volatility but not extreme risks [7]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector is expected to continue its recovery, with a focus on innovative drugs as the main investment theme. The report highlights a gradual improvement in the industry, with Q2 showing a significant reduction in the decline of revenue and profits compared to Q1 [7][21][19] - The report emphasizes the potential for a turnaround in the industry, driven by policy improvements, demand recovery, and the performance of the CRO/CDMO segments [10][16] Summary by Sections Market Performance - In August 2025, the pharmaceutical and biotechnology sector rose by 2.6%, underperforming the Shanghai and Shenzhen 300 index, which increased by 10.3%. The sector ranked 24th among 31 sub-industries [7][15] - The report notes a mixed performance among sub-sectors, with medical devices and services showing gains, while the pharmaceutical commercial sector declined [15] Financial Performance - In the first half of 2025, the cumulative revenue of pharmaceutical companies decreased by 2.6%, with total profits down by 4.0%. However, Q2 showed a narrowing of declines, with revenue down by only 1.1% and total profits down by 2.9% [21][19] - The report indicates that the CRO/CDMO segments performed well, with significant revenue and profit growth, particularly in Q2 [21][19] Investment Opportunities - The report suggests focusing on innovative drugs, which are seen as having strong growth potential and clear industry trends. It recommends several companies across different categories, including biotech firms transitioning to biopharma and large pharmaceutical companies involved in innovative drug development [9][10][11] - The report also highlights the potential for recovery in the CRO/CDMO segments and suggests that companies in these areas are likely to benefit from improving demand and order recovery [10][16] Key Recommendations - The report lists key companies to watch, including WuXi AppTec, WuXi Biologics, and others, indicating a positive outlook for these firms based on their performance and market position [17][18]